Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available Clinical Trials

SCLC - immunotherapy + chemotherapy

Clinical Study of an Investigational Immunotherapy for First line Treatment of Advanced Cancer (TIGOS)

Contact:

Phone Number: 855.907.3286
Email: [email protected]

About this trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy given with chemotherapy compared to standard of care immunotherapy given with chemotherapy in people with extensive-stage small cell lung cancer who have not received prior treatment for advanced disease.

Participants who qualify will be assigned to receive one of the two treatment approaches.

The purpose of the study is to compare the safety and effectiveness of the investigational treatment and to help determine whether it may offer benefit for patients in the future.

Who can participate:

The study is open to patients with extensive-stage small cell lung cancer who have not received prior systemic treatment for advanced disease and are able to meet the study requirements.
 

Learn More

NSCLC - nivolumab and relatlimab

Clinical Study of Nivolumab and Relatlimab for First line Treatment of Advanced Non Small Cell Lung Cancer (RELATIVITY 1093)

Contact:

Phone Number: 855.907.3286
Email: [email protected]

About the trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy combination given with chemotherapy compared to a standard immunotherapy plus chemotherapy in people with advanced or recurrent non small cell lung cancer (NSCLC) who have not received prior treatment for advanced disease. 

Participants who qualify will be assigned to receive one of the two options.

The purpose of the study is to compare the safety and effectiveness of these approaches and to help determine whether the investigational treatments may offer benefit for patients in the future.
 

Learn More

HER2 NSCLC - sevabertinib

Study to Learn How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared to Standard Treatment, in People Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Contact:

Phone Number: (+)1-888-84 22937 
Email: [email protected]

About the trial:

This is a study to learn more about how well sevabertinib works and how safe it is compared with standard treatment. If patients pass the screening phase, they will receive either sevabertinib (study drug) or chemo immunotherapy (standard of care). 

Who can participate:

The following are a few requirements patients should have in order to participate in the study: 

  1. Documented diagnosis of advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations
  2. No previous treatment for this specific diagnosis 
  3. Ability to swallow oral medication and comply with study requirements

Learn More

*These trials are listed for a period of 3 months.